Table 5.
HRs of Hepatocellular Carcinoma Development by Cirrhosis and Differently Adjusted Models (All Study Participants)
| Model | HR | 95% CI | p-value |
|---|---|---|---|
| Unadjusted | 8.454 | 4.825–14.813 | <0.001 |
| Adjusted | |||
| Model 1 | 6.957 | 3.957–12.231 | <0.001 |
| Model 2 | 7.020 | 3.992–12.347 | <0.001 |
| Model 3 | 5.257 | 2.795–9.885 | <0.001 |
| Model 4 | 5.117 | 2.754–9.733 | <0.001 |
| Model 5 | 4.337 | 2.301–8.177 | <0.001 |
| Model 6 | 4.095 | 2.148–7.807 | <0.001 |
HR, hazard ratio; CI, confidence interval; HBeAg, hepatitis B e antigen; HBV, hepatitis B virus; AVT, antiviral therapy.
Model 1, age and gender; model 2, model 1 + diabetes mellitus; model 3, model 3 + α-fetoprotein, HBeAg positivity, HBV DNA, aspartate aminotransferase, alanine aminotransferase, serum albumin, total bilirubin, and platelet count; model 4, model 3 + AVT at enrollment; model 5, model 4 + AVT after enrollment; model 6, model 5 + institution.